Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics. 1999

F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
Center for Advanced Radiation Therapies, Idaho National Engineering and Environmental Laboratory, Idaho Falls 83415-3890, USA.

The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.

UI MeSH Term Description Entries
D009010 Monte Carlo Method In statistics, a technique for numerically approximating the solution of a mathematical problem by studying the distribution of some random variable, often generated by a computer. The name alludes to the randomness characteristic of the games of chance played at the gambling casinos in Monte Carlo. (From Random House Unabridged Dictionary, 2d ed, 1993) Method, Monte Carlo
D009502 Neutrons Electrically neutral elementary particles found in all atomic nuclei except light hydrogen; the mass is equal to that of the proton and electron combined and they are unstable when isolated from the nucleus, undergoing beta decay. Slow, thermal, epithermal, and fast neutrons refer to the energy levels with which the neutrons are ejected from heavier nuclei during their decay. Neutron
D009688 Nuclear Reactors Devices containing fissionable material in sufficient quantity and so arranged as to be capable of maintaining a controlled, self-sustaining NUCLEAR FISSION chain reaction. They are also known as atomic piles, atomic reactors, fission reactors, and nuclear piles, although such names are deprecated. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Nuclear Reactor,Reactor, Nuclear,Reactors, Nuclear
D010315 Particle Accelerators Devices which accelerate electrically charged atomic or subatomic particles, such as electrons, protons or ions, to high velocities so they have high kinetic energy. Betatrons,Linear Accelerators,Accelerator, Linear,Accelerator, Particle,Accelerators, Linear,Accelerators, Particle,Betatron,Linear Accelerator,Particle Accelerator
D011336 Probability The study of chance processes or the relative frequency characterizing a chance process. Probabilities
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001896 Boron Compounds Inorganic or organic compounds that contain boron as an integral part of the molecule. Borides,Compounds, Boron
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain

Related Publications

F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
January 1997, Biomedizinische Technik. Biomedical engineering,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
January 2011, Duodecim; laaketieteellinen aikakauskirja,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
November 2023, Pharmaceutics,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
March 1994, International journal of radiation oncology, biology, physics,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
December 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
January 2021, Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
February 2022, Molecular pharmaceutics,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
October 2008, Critical reviews in oncology/hematology,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
December 1988, The British journal of radiology,
F J Wheeler, and D W Nigg, and J Capala, and P R Watkins, and C Vroegindeweij, and I Auterinen, and T Seppälä, and D Bleuel
December 2017, Radiological physics and technology,
Copied contents to your clipboard!